- Home
- ETON vs ALVR Comparison
ETON vs ALVR Comparison
Compare ETON & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- ALVR
- Stock Information
- Founded
- ETON 2017
- ALVR 2013
- Country
- ETON United States
- ALVR United States
- Employees
- ETON N/A
- ALVR N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ETON Health Care
- ALVR Health Care
- Exchange
- ETON Nasdaq
- ALVR Nasdaq
- Market Cap
- ETON 199.5M
- ALVR 87.7M
- IPO Year
- ETON 2018
- ALVR 2020
- Fundamental
- Price
- ETON $8.82
- ALVR $0.90
- Analyst Decision
- ETON Strong Buy
- ALVR Sell
- Analyst Count
- ETON 3
- ALVR 5
- Target Price
- ETON $12.00
- ALVR $1.00
- AVG Volume (30 Days)
- ETON 214.1K
- ALVR 155.6K
- Earning Date
- ETON 11-11-2024
- ALVR 11-04-2024
- Dividend Yield
- ETON N/A
- ALVR N/A
- EPS Growth
- ETON N/A
- ALVR N/A
- EPS
- ETON N/A
- ALVR N/A
- Revenue
- ETON $31,381,000.00
- ALVR N/A
- Revenue This Year
- ETON $19.61
- ALVR N/A
- Revenue Next Year
- ETON $35.39
- ALVR N/A
- P/E Ratio
- ETON N/A
- ALVR N/A
- Revenue Growth
- ETON 8.14
- ALVR N/A
- 52 Week Low
- ETON $3.03
- ALVR $0.58
- 52 Week High
- ETON $8.66
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- ETON 76.07
- ALVR 69.10
- Support Level
- ETON $7.58
- ALVR $0.74
- Resistance Level
- ETON $8.66
- ALVR $0.91
- Average True Range (ATR)
- ETON 0.42
- ALVR 0.06
- MACD
- ETON -0.07
- ALVR 0.01
- Stochastic Oscillator
- ETON 91.49
- ALVR 94.50
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.